Matsuyama Arata, Schott Courtney R, Wood Geoffrey A, Richardson Danielle, Woods J Paul, Mutsaers Anthony J
J Am Vet Med Assoc. 2018 Jun 1;252(11):1377-1383. doi: 10.2460/javma.252.11.1377.
OBJECTIVE To determine the effectiveness of metronomic cyclophosphamide (MC) chemotherapy (primary treatment of interest) with adjuvant meloxicam administration as maintenance treatment for dogs with appendicular osteosarcoma following limb amputation and carboplatin chemotherapy. DESIGN Retrospective case series with nested cohort study. ANIMALS 39 dogs with a histologic diagnosis of appendicular osteosarcoma that underwent limb amputation and completed carboplatin chemotherapy from January 2011 through December 2015. PROCEDURES Dogs were grouped by whether carboplatin chemotherapy had been followed with or without MC chemotherapy (15 mg/m, PO, q 24 h) and meloxicam (0.1 mg/kg [0.045 mg/lb], PO, q 24 h). The Breslow rank test was used to assess whether MC chemotherapy was associated with overall survival time (OST) and disease progression-free time (PFT) after limb amputation. RESULTS 19 dogs received carboplatin and MC chemotherapy, and 20 dogs received only carboplatin chemotherapy. No differences were identified between these groups regarding age, reproductive status, body weight, serum alkaline phosphatase activity, tumor location, or histologic grade or subtype of osteosarcoma. Median duration of MC chemotherapy for dogs in the carboplatin-MC group was 94 days (range, 7 to 586 days); this treatment was discontinued for 11 (58%) dogs when cystitis developed. Overall, 11 (28%) dogs survived to the time of analysis, for a median follow-up period of 450 days (range, 204 to 1,400 days). No difference in median PFT or OST was identified between the 2 groups. CONCLUSIONS AND CLINICAL RELEVANCE Maintenance MC chemotherapy following limb amputation and completed carboplatin chemotherapy was associated with no increase in PFT or OST in dogs with appendicular osteosarcoma. Cystitis was common in MC-treated dogs, and prophylactic treatment such as furosemide administration could be considered to reduce the incidence of cystitis in such dogs.
目的 确定节拍性环磷酰胺(MC)化疗(主要研究的治疗方法)联合辅助使用美洛昔康作为肢体截肢和卡铂化疗后的犬附肢骨肉瘤维持治疗的有效性。 设计 带有巢式队列研究的回顾性病例系列。 动物 39只经组织学诊断为附肢骨肉瘤的犬,于2011年1月至2015年12月期间接受了肢体截肢并完成了卡铂化疗。 程序 根据卡铂化疗后是否接受MC化疗(15 mg/m²,口服,每24小时一次)和美洛昔康(0.1 mg/kg [0.045 mg/lb],口服,每24小时一次)对犬进行分组。采用Breslow秩和检验评估MC化疗与肢体截肢后的总生存时间(OST)和无疾病进展时间(PFT)是否相关。 结果 19只犬接受了卡铂和MC化疗,20只犬仅接受了卡铂化疗。在这些组之间,关于年龄、生殖状态、体重、血清碱性磷酸酶活性、肿瘤位置或骨肉瘤的组织学分级或亚型未发现差异。卡铂-MC组犬的MC化疗中位持续时间为94天(范围为7至586天);当膀胱炎发生时,11只(58%)犬停止了该治疗。总体而言,11只(28%)犬存活至分析时,中位随访期为450天(范围为204至1400天)。两组之间的中位PFT或OST未发现差异。 结论及临床意义 肢体截肢和完成卡铂化疗后进行维持性MC化疗与犬附肢骨肉瘤的PFT或OST增加无关。膀胱炎在接受MC治疗的犬中很常见,可以考虑使用速尿等预防性治疗来降低此类犬膀胱炎的发生率。